KDA
- Current
- Browse
- Collections
-
For contributors
- For Authors
- Instructions to authors
- Article processing charge
- e-submission
- For Reviewers
- Instructions for reviewers
- How to become a reviewer
- Best reviewers
- For Readers
- Readership
- Subscription
- Permission guidelines
- About
- Editorial policy
Search
- Page Path
- HOME > Search
- Various Oscillation Patterns of Serum Fibroblast Growth Factor 21 Concentrations in Healthy Volunteers
- Sang Ah Lee, Eunheiu Jeong, Eun Hee Kim, Mi-Seon Shin, Jenie Yoonoo Hwang, Eun Hee Koh, Woo Je Lee, Joong-Yeol Park, Min-Seon Kim
- Diabetes Metab J. 2012;36(1):29-36. Published online February 17, 2012
- DOI: https://doi.org/10.4093/dmj.2012.36.1.29
- 3,671 View
- 32 Download
- 13 Crossref
-
Abstract
PDF
PubReader Background Fibroblast growth factor 21 (FGF21) was originally identified as a paroxysm proliferator activated receptor-α target gene product and is a hormone involved in metabolic regulation. The purpose of this study was to investigate the diurnal variation of serum FGF21 concentration in obese and non-obese healthy volunteers.
Methods Blood samples were collected from five non-obese (body mass index [BMI] ≤23 kg/m2) and five obese (BMI ≥25 kg/m2) healthy young men every 30 to 60 minutes over 24 hours. Serum FGF21 concentrations were determined by radioimmunoassay. Anthropometric parameters, glucose, free fatty acid, insulin, leptin, and cortisol concentrations were also measured.
Results The serum FGF21 concentrations displayed various individual oscillation patterns. The oscillation frequency ranged between 6 and 12 times per day. The average duration of oscillation was 2.52 hours (range, 1.9 to 3.0 hours). The peaks and troughs of FGF21 oscillation showed no circadian rhythm. However, the oscillation frequency had a diurnal variation and was lower during the light-off period than during the light-on period (2.4 vs. 7.3 times,
P <0.001). There was no difference in the total frequency or duration of oscillations between non-obese and obese subjects, but obese individuals had increased numbers of larger oscillations (amplitude ≥0.19 ng/mL).Conclusion Various oscillation patterns in serum FGF21 concentration were observed, and reduced oscillation frequencies were seen during sleep. The oscillation patterns of serum FGF21 concentration suggest that FGF21 may be secreted into systemic circulation in a pulsatile manner. Obesity appeared to affect the amplitude of oscillations of serum FGF21.
-
Citations
Citations to this article as recorded by
- Circadian Regulation of Endocrine Fibroblast Growth Factors on Systemic Energy Metabolism
Zhenning Yang, Helmut Zarbl, Grace L. Guo
Molecular Pharmacology.2024; 105(3): 179. CrossRef - Acute sleep loss alters circulating fibroblast growth factor 21 levels in humans: A randomised crossover trial
Luiz Eduardo Mateus Brandão, Daniel Espes, Jakub Orzechowski Westholm, Teemu Martikainen, Nestori Westerlund, Lauri Lampola, Alexandru Popa, Heike Vogel, Annette Schürmann, Suzanne L. Dickson, Christian Benedict, Jonathan Cedernaes
Journal of Sleep Research.2022;[Epub] CrossRef - Metabolic Stress Index Including Mitochondrial Biomarker for Noninvasive Diagnosis of Hepatic Steatosis
Jae Seung Chang, Jhii-Hyun Ahn, Seong Hee Kang, Sang-Baek Koh, Jang-Young Kim, Soon Koo Baik, Ji Hye Huh, Samuel S. Lee, Moon Young Kim, Kyu-Sang Park
Frontiers in Endocrinology.2022;[Epub] CrossRef - Single-Arm 8-Week Ad Libitum Self-Prepared Paleo Diet Reduces Cardiometabolic Disease Risk Factors in Overweight Adults
Melissa M. Markofski, Kristofer Jennings, Chad Dolan, Natalie A. Davies, Emily C. LaVoy, Edward J. Ryan, Andres E. Carrillo
American Journal of Lifestyle Medicine.2021; 15(6): 690. CrossRef - Diurnal rhythm in clinical chemistry: An underrated source of variation
Mohamed Abou El Hassan, Edgard Delvin, Manal O. Elnenaei, Barry Hoffman
Critical Reviews in Clinical Laboratory Sciences.2018; 55(8): 516. CrossRef - Integrated stress response stimulates FGF21 expression: Systemic enhancer of longevity
Antero Salminen, Kai Kaarniranta, Anu Kauppinen
Cellular Signalling.2017; 40: 10. CrossRef - Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
Chiara Degirolamo, Carlo Sabbà, Antonio Moschetta
Nature Reviews Drug Discovery.2016; 15(1): 51. CrossRef - Response of fibroblast growth factor 21 to meal intake and insulin infusion in patients on maintenance haemodialysis
Mark Reinhard, Jan Frystyk, Bente Jespersen, Else Randers, Bo Martin Bibby, Per Ivarsen
Clinical Endocrinology.2015; 83(2): 187. CrossRef - Possible role of fibroblast growth factor 21 on atherosclerosis via amelioration of endoplasmic reticulum stress-mediated apoptosis in apoE−/− mice
Xi Wu, Yong-Fen Qi, Jin-Rui Chang, Wei-Wei Lu, Jin-Sheng Zhang, Shao-Ping Wang, Shu-Juan Cheng, Ming Zhang, Qian Fan, Yuan Lv, Hui Zhu, Man-Kun Xin, Yun Lv, Jing-Hua Liu
Heart and Vessels.2015; 30(5): 657. CrossRef - Circulating Fibroblast Growth Factors as Metabolic Regulators—A Critical Appraisal
Bo Angelin, Tobias E. Larsson, Mats Rudling
Cell Metabolism.2012; 16(6): 693. CrossRef - Metabolic actions of fibroblast growth factor 21
Daniel Cuevas-Ramos, Carlos A. Aguilar-Salinas, Francisco J. Gómez-Pérez
Current Opinion in Pediatrics.2012; 24(4): 523. CrossRef - Fibroblast Growth Factor 21: A Novel Metabolic Regulator
Ji A Seo, Nan Hee Kim
Diabetes & Metabolism Journal.2012; 36(1): 26. CrossRef - MECHANISMS IN ENDOCRINOLOGY: Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21
Pedro Iglesias, Rafael Selgas, Sara Romero, Juan J Díez
European Journal of Endocrinology.2012; 167(3): 301. CrossRef
- Circadian Regulation of Endocrine Fibroblast Growth Factors on Systemic Energy Metabolism
First
Prev
